Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Amgen and Kite Pharma entered into a strategic research collaboration to advance CAR T immunotherapy beyond CD19 by combining Amgen's oncology targets with…
Novel CAR T-cell therapies expected from the Amgen/Kite Pharma collaboration, leveraging Kite's engineered autologous platform with Amgen's deep oncology…
Kite Pharma was acquired by Gilead for $11.9B in October 2017; the prior Amgen collaboration ultimately did not produce a publicly disclosed launched asset.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Amgen and Kite Pharma announced a strategic research collaboration and license agreement to develop and commercialize CAR T cell immunotherapies based on Kite's engineered autologous cell therapy platform and Amgen's array of cancer targets. Kite received $60M upfront and was eligible for up to $525M in milestones per Amgen program plus tiered royalties; Amgen also eligible for $525M per Kite program.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Amgen Inc. / Kite Pharma, Inc. (this deal) | 2015 | $585M | — |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Amgen Inc. / Five Prime Therapeutics | 2021 | $1.9B | 78 |
| Amgen Inc. / Horizon Therapeutics plc | 2022 | $27.8B | 72 |
| Amgen Inc. / Otezla (from Celgene/BMS) | 2019 | $13.4B | 68 |
← Browse all deals · How we score deals
More: 2015 deals · Amgen Inc. deals · Hematology deals